{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:56:52Z","timestamp":1784339812042,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.eprac.2021.05.012","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T02:04:34Z","timestamp":1623031474000},"page":"941-947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis"],"prefix":"10.1016","volume":"27","author":[{"given":"Tomaz","family":"Kocjan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonela Sabati","family":"Rajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Janez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaj","family":"Vidmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Orehek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja","family":"Marc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ostanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2021.05.012_bib1","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society\u2217 Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2021.05.012_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-020-05303-5","volume":"31","author":"Kanis","year":"2020","journal-title":"Published correction appears in Osteoporos Int"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.05.012_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.eprac.2021.05.012_bib4","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.eprac.2021.05.012_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.eprac.2021.05.012_bib6","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"18","key":"10.1016\/j.eprac.2021.05.012_bib7","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2021.05.012_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12020-019-01919-8","article-title":"The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment","volume":"64","author":"Gua\u00f1abens","year":"2019","journal-title":"Endocrine"},{"issue":"9999","key":"10.1016\/j.eprac.2021.05.012_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib10","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2021.05.012_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","article-title":"The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis","volume":"35","author":"Ebina","year":"2017","journal-title":"J\u00a0Bone Miner Metab"},{"issue":"5","key":"10.1016\/j.eprac.2021.05.012_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jbm4.10054","article-title":"Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial","volume":"2","author":"Niimi","year":"2018","journal-title":"JBMR Plus"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00198-018-4434-8","article-title":"Effects of bone remodeling agents following teriparatide treatment","volume":"29","author":"Burkard","year":"2018","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.eprac.2021.05.012_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.eprac.2021.05.012_bib16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group","volume":"283","author":"Cummings","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2021.05.012_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","article-title":"Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary","volume":"7","author":"Orimo","year":"2012","journal-title":"Arch Osteoporos"},{"issue":"2","key":"10.1016\/j.eprac.2021.05.012_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib19","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.eprac.2021.05.012_bib20","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jc.2005-1712","article-title":"Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis","volume":"91","author":"Bauer","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib21","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-010-1379-y","article-title":"Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide","volume":"22","author":"Blumsohn","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2021.05.012_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2016.11.009","article-title":"Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study","volume":"95","author":"Tsai","year":"2017","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.eprac.2021.05.012_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.eprac.2021.05.012_bib25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","article-title":"PINP as a biological response marker during teriparatide treatment for osteoporosis","volume":"25","author":"Krege","year":"2014","journal-title":"Osteoporos Int"},{"issue":"15","key":"10.1016\/j.eprac.2021.05.012_bib26","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.05.012_bib27","first-page":"S150","article-title":"Biochemical markers predict spine but not hip BMD response to alendronate: the fracture intervention trial (FIT)","volume":"12","author":"Bauer","year":"1997","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.eprac.2021.05.012_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial","volume":"21","author":"Bauer","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.eprac.2021.05.012_bib29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1210\/jc.2015-2446","article-title":"The influence of serum uric acid on bone mineral density, hip geometry, and fracture risk: the Rotterdam Study","volume":"101","author":"Muka","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2021.05.012_bib30","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/aps.2017.165","article-title":"Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population","volume":"39","author":"Yan","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.eprac.2021.05.012_bib31","doi-asserted-by":"crossref","first-page":"3082318","DOI":"10.1155\/2020\/3082318","article-title":"The association between serum uric acid and bone mineral density in older adults","volume":"2020","author":"Yao","year":"2020","journal-title":"Int J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2021.05.012_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11657-017-0345-0","article-title":"Association between lumbar bone mineral density and serum uric acid in postmenopausal women: a cross-sectional study of healthy Chinese population","volume":"12","author":"Han","year":"2017","journal-title":"Arch Osteoporos"},{"issue":"3","key":"10.1016\/j.eprac.2021.05.012_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1871530318666181102115106","article-title":"Review of the literature examining the association of serum uric acid with osteoporosis and mechanistic insights into its effect on bone metabolism","volume":"19","author":"Kaushal","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"9","key":"10.1016\/j.eprac.2021.05.012_bib34","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/nu11092111","article-title":"The paradoxical role of uric acid in osteoporosis","volume":"11","author":"Lin","year":"2019","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.eprac.2021.05.012_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.eprac.2021.05.012_bib36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"issue":"4","key":"10.1016\/j.eprac.2021.05.012_bib37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1210\/jc.2008-1122","article-title":"Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates","volume":"94","author":"Burnett-Bowie","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib38","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","article-title":"Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate","volume":"22","author":"Kendler","year":"2011","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.eprac.2021.05.012_bib39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.eprac.2021.05.012_bib40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21010776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21010776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:10:45Z","timestamp":1761516645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X21010776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1530891X21010776"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.05.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}